ENZN · Enzon Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $26.0K | - | $26.0K | $701.0K | $52.0K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - |
| Total Operating Expenses | $5.31M | $1.35M | $1.04M | $1.06M | $1.17M | $1.36M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($5.31M) | ($1.33M) | ($1.04M) | ($1.03M) | ($469.0K) | ($1.30M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $19.0K | $347.0K | ($156.0K) | ($200.0K) | $7.0K | $7.0K |
| Net Income | ($3.41M) | $778.0K | $1.37M | ($186.0K) | ($469.0K) | ($1.31M) |
| EPS - Basic | ($0.07) | ($0.01) | $0.00 | ($0.02) | ($0.03) | - |
| EPS - Diluted | ($0.07) | ($0.01) | $0.00 | ($0.02) | ($0.03) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.57M | $46.86M | $47.01M | $46.98M | $47.64M | $48.14M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $331.0K | $331.0K | $331.0K | $331.0K | $331.0K | $302.0K |
| Current Assets | $42.81M | $47.15M | $47.34M | $47.39M | - | $48.23M |
| Total Assets | $42.81M | $47.17M | $47.70M | $47.59M | $47.75M | $48.23M |
| Current Liabilities | $731.0K | $1.68M | $1.71M | $1.70M | $403.0K | $412.0K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($2.52M) | $3.01M | $3.50M | $3.41M | $4.87M | $7.36M |
| Retained Earnings | ($73.30M) | ($69.89M) | ($70.67M) | ($72.04M) | ($71.86M) | ($71.39M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.01M) | $1.12M | $1.30M | ($659.0K) | ($501.0K) | ($380.0K) |
| Investing Cash Flow | - | - | - | - | - | - |
| Financing Cash Flow | ($1.27M) | ($1.27M) | ($1.27M) | - | $0 | $43.08M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | -5103.8% | - | -3969.2% | -66.9% | -2509.6% |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | 2992.3% | - | -715.4% | -66.9% | -2521.2% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | 30.8% | -12.8% | - | - | - |
| Return on assets | -8.0% | 1.6% | 2.9% | -0.4% | -1.0% | -2.7% |
| Return on equity | 135.0% | 25.9% | 39.2% | -5.5% | -9.6% | -17.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 58.57 | 28.10 | 27.62 | 27.89 | - | 117.07 |
| Quick ratio | 58.57 | 28.10 | 27.62 | 27.89 | - | 117.07 |
| Cash ratio | 58.24 | 27.93 | 27.43 | 27.65 | 118.22 | 116.85 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -16.96 | 15.68 | 13.61 | 13.97 | 9.81 | 6.55 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | 0.00 | - | 0.00 | 0.01 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 3.9x | 1.9x | - | - | - |
| P / S | - | 456.7x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | -96.3% | 1248.1% | -74.9% |
| Revenue CAGR (3y) | - | -66.7% | - | -49.9% | -56.3% | -81.6% |
| Revenue CAGR (5y) | - | -34.0% | - | -68.5% | -39.1% | -68.8% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -300.2% | -27.1% | -1.2% | -120.0% | 64.1% | -34.1% |
| Net income growth (YoY) | - | -43.3% | - | 60.3% | 64.2% | -33.9% |
| EPS growth (YoY) | -600.0% | - | - | 33.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -14.2% | 2.9% | -30.0% | -33.9% | 21.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$22.0K totalRoyalty$22.0K · 100.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ENZON PHARMACEUTICALS against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Sep 30, 2019 | $0.1200 |
| Feb 20, 2019 | $0.0600 |
| Sep 29, 2017 | $0.1500 |
| Dec 13, 2016 | $0.1500 |
| Dec 30, 2015 | $0.2500 |
| Aug 13, 2015 | $0.5000 |
| Jan 8, 2015 | $0.1000 |
| Dec 24, 2013 | $0.4500 |
| Jun 5, 2013 | $1.6000 |
| Dec 6, 2012 | $2.0000 |